Prolongation of GLP-1 Adherence When Using Continuous Glucose Monitoring

Recruiting Observational Study
Diabetes Mellitus
No Placebo Group Every participant receives an active treatment — no one gets a placebo. No Study Drug Researchers observe your health over time — no experimental treatment is given.
Ready to participate?

Review the details below, then apply to join this clinical trial.

At a Glance
Age
18 and older
Sex
Any
Study type
Observational
Participants needed
800 (estimated)
Sponsor
Abbott Diabetes Care · Industry
Think this trial could be right for you?

Answer three quick questions written from this study's own rules to see if you may qualify. No account needed to find out.

Check Your Eligibility
About This Trial

This study is to see if the FreeStyle Libre 3 Continuous Glucose Monitoring System (FSL3) will help prolong the length of time people with diabetes maintain adherence to glucagon-like peptide 1 (GLP-1/GIP) agonists.

Trial Locations
Loading…

Loading trial locations…

Eligibility Criteria
Inclusion Criteria: 1. Subject must be at least 18 years of age. 2. Subject must be able to read and understand English. 3. Subject must have a type 2 diabetes diagnosis. 4. In the investigator's opinion, subject must meet the criteria for beginning use of GLP-1 or GIP/GLP-1 medications for managem…
Contacts

Mohamed Mohamed Nada, PhD

5107495416

adc.clinical@abbott.com

CONTACT

Shridhara Karinka, PhD

510 7495416

adc.clinical@abbtott.com

CONTACT